These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30401353)

  • 21. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
    Soyka M; Hillemacher T
    Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent advances in the treatment of opiate addiction.
    Fudala PJ; Woody GW
    Curr Psychiatry Rep; 2004 Oct; 6(5):339-46. PubMed ID: 15355756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of opioid use disorder in primary care.
    Buresh M; Stern R; Rastegar D
    BMJ; 2021 May; 373():n784. PubMed ID: 34011512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medications for addiction treatment initiated from the emergency department: Ethical considerations.
    Marshall KD; Derse AR; Iserson KV; Kluesner N; Vearrier L
    Am J Emerg Med; 2020 Feb; 38(2):343-348. PubMed ID: 31831343
    [No Abstract]   [Full Text] [Related]  

  • 25. Association of a Multimodal Educational Intervention for Primary Care Physicians With Prescriptions of Buprenorphine for Opioid Use Disorders.
    Clark B; Kai M; Dix R; White J; Rozenfeld Y; Levy S; Engstrom K
    JAMA Netw Open; 2019 Oct; 2(10):e1913818. PubMed ID: 31642929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rural access to MAT in Pennsylvania (RAMP): a hybrid implementation study protocol for medication assisted treatment adoption among rural primary care providers.
    Cochran G; Cole ES; Warwick J; Donohue JM; Gordon AJ; Gellad WF; Bear T; Kelley D; DiDomenico E; Pringle J
    Addict Sci Clin Pract; 2019 Aug; 14(1):25. PubMed ID: 31366408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine Provision by Early Career Family Physicians.
    Tong ST; Hochheimer CJ; Peterson LE; Krist AH
    Ann Fam Med; 2018 Sep; 16(5):443-446. PubMed ID: 30201642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overcoming Barriers to Initiating Medication-assisted Treatment for Heroin Use Disorder in a General Medical Hospital: A Case Report and Narrative Literature Review.
    Hassamal S; Goldenberg M; Ishak W; Haglund M; Miotto K; Danovitch I
    J Psychiatr Pract; 2017 May; 23(3):221-229. PubMed ID: 28492461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatments for opioid use disorder among pregnant and reproductive-aged women.
    Hand DJ; Short VL; Abatemarco DJ
    Fertil Steril; 2017 Aug; 108(2):222-227. PubMed ID: 28697916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders.
    Scholzen E; Zeng AM; Schroeder KM
    Adv Anesth; 2019 Dec; 37():65-86. PubMed ID: 31677660
    [No Abstract]   [Full Text] [Related]  

  • 32. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.
    Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP
    J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facilitators and Barriers to Naloxone Kit Use Among Opioid-Dependent Patients Enrolled in Medication Assisted Therapy Clinics in North Carolina.
    Khatiwoda P; Proeschold-Bell RJ; Meade CS; Park LP; Proescholdbell S
    N C Med J; 2018; 79(3):149-155. PubMed ID: 29735615
    [No Abstract]   [Full Text] [Related]  

  • 34. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
    Balhara YP
    J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
    Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
    Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Buprenorphine to Treat Opioid Use Disorder.
    Bartholow LAM; Pope J
    J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder.
    Miller JC; Brooks MA; Wurzel KE; Cox EJ; Wurzel JF
    Drugs R D; 2023 Dec; 23(4):339-362. PubMed ID: 37938531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapies for treating opioid use disorder.
    Nguyen TA; Hahn JH; Strakowski SM
    CNS Spectr; 2013 Dec; 18(6):289-95. PubMed ID: 23561653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buprenorphine offers a way to rise from the ashes of addiction.
    Newcomb A
    J Fam Pract; 2021 Sep; 70(7):317. PubMed ID: 34818160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.